JJP Biologicssp. z o.o.
Research and experimental development in natural sciences and engineering
Overview
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-05-25. Active
15 1140 1010 0000 5562 9900 1003
16 1020 1026 0000 1302 0465 7369- 25 1020 1026 0000 1102 0465 5850
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 5, 2024 | Call to creditors | |
| Nov 18, 2020 | Call to creditors |
Public aid
13 public aid cases recorded, with a total value of $22,776,051.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 30, 2026 | Aid for research and development projects: experimental development | $4.4M$4,395,379 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 30, 2026 | Aid for research and development projects: industrial research | $4.2M$4,247,344 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Apr 1, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $18,834$18,834 | Pomorska Specjalna Strefa Ekonomiczna sp. z o.o. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-04-01 | Opracowanie innowacyjnej cząsteczki, przeznaczonej do immunoterapii gruczolakoraka płuc, indukującej mechanizm ukierunkowanej degradacji lizosomalnej | $8.4M$8,357,172 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The making of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
| 57,580 | $777,687.74 | 89.9997% | |
Jerzy Andrzej Starak | 6,398 | $86,169.64 | 9.9722% |
Others | 18 | $243.11 | 0.0281% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Julia Anastazja Starak (37)  | Posiadanie udziałów w spółce z o.o. będącej właścicielem 90% udziałów zgłaszanej spółki | |
Patrick Rafał Starak (53) | Posiadanie udziałów w spółce z o.o. będącej właścicielem 90% udziałów zgłaszanej spółki |
Subsidiaries
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Fluence Technologysp. z o.o. | $2,486,673.06 | fluence.pl | ||
| Oncotransfersp. z o.o. | $704,767.72 | oncotransfer.pib-nio.pl | ||
| Smart FluidS.A. | $681,963.98 | smartfluid.pl | ||
| Lymelab Pharma sp. z o.o.sp. k. | $424,756.39 | lymelabpharma.com | ||
| Oasis DiagnosticsS.A. | $282,613.94 | oasis-diagnostics.com | ||
| NanosanguisS.A. | $192,701.50 | nanosanguis.com | ||
| Codeit4us Rndsp. z o.o. | $152,435.96 | codeit4us.com | ||
| VB IdeaP.S.A. | $44,631.63 | vbidea.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com |
Change history
| Date | Event | |
|---|---|---|
| 2025-12-05 | Share capital change (2,879,000.00 PLN → 3,198,900.00 PLN) | |
| 2025-05-19 | PKD change (Removed: 64.92.Z, 70.22.Z, 72.11.Z, 72.19.Z, 74.90.Z, 77.40.Z, 82.99.Z; Added: 64.21.Z, 64.22.Z, 70.20.Z, 72.10.Z, 74.99.Z, 77.40.B, 82.99.B) | |
| 2024-07-03 | Share capital change (58,980,000.00 PLN → 2,879,000.00 PLN) | |
| 2022-12-01 | Address change (Ul. Bobrowiecka 8, 00-728, Warszawa → Ul. Bobrowiecka 6, 00-728, Warszawa) | |
| 2022-05-01 | Share capital change (2,505,000.00 PLN → 58,980,000.00 PLN) |
FAQ
Last updated: 2026-07-20